This statement really sticks out to me.
”Anoutcome of 15 PR’s or more, by the end of the study, would indicate the narmafotinib combinationperforms better than chemotherapy alone. The drug continues to be well tolerated by patients withthe rate and type of adverse events for the narmafotinib combination being very similar to thatreported for chemotherapy alone“.
Ann: Encouraging Updated Data from Pancreatic Cancer Trial, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.025(12.8%) |
Mkt cap ! $85.34M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 22.5¢ | 19.0¢ | $939.8K | 4.509M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 21.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.0¢ | 61514 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| ATX (ASX) Chart |